CD8A and myasthenia gravis: In a previous study, peripheral blood mononuclear cellular typing was performed before and after nivolumab treatment in a patient who developed MG/myositis/myocarditis, and revealed an increased expression of CD8 and cytolytic activity markers, whereas CD4 T-cell and T-regulatory cell activity were suppressed (14).